Review of Patient Decision Aids for Psoriasis
Author(s)
Anna López Ferrer, MD, PhD1, Isabel Belinchón, MD, PhD2, Marta Comellas Serra, PharmD3, Míriam Garrido Clua, MASc3, Alberto Romero Mate, MD4, Beatriz Pérez Suárez, MD5, Sergio Santos Alarcón, MD6, Pablo de la Cueva, MD, PhD7.
1Department of Dermatology, Hospital Santa Creu i Sant Pau, Barcelona, Spain, 2Department of Clinical Medicine, Dr. Balmis General University Hospital, Alicante, Spain, 3Outcomes'10 (a Productlife Group company), Castellón de la Plana, Spain, 4Department of Dermatology, Hospital Universitario de Fuenlabrada, Madrid, Spain, 5Department of Dermatology, Hospital Morales Meseguer, Murcia, Spain, 6Hospital Universitario Doctor Peset, Valencia, Spain, 7Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain.
1Department of Dermatology, Hospital Santa Creu i Sant Pau, Barcelona, Spain, 2Department of Clinical Medicine, Dr. Balmis General University Hospital, Alicante, Spain, 3Outcomes'10 (a Productlife Group company), Castellón de la Plana, Spain, 4Department of Dermatology, Hospital Universitario de Fuenlabrada, Madrid, Spain, 5Department of Dermatology, Hospital Morales Meseguer, Murcia, Spain, 6Hospital Universitario Doctor Peset, Valencia, Spain, 7Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain.
OBJECTIVES: Patient decision aids (PDAs) play a critical role in supporting shared decision-making by helping patients understand their options and incorporate their preferences into care decisions, ultimately improving treatment adherence and satisfaction. This study aimed to conduct a structured literature review to identify and analyze PDAs developed for patients with psoriasis.
METHODS: A defined search strategy was used to identify literature on decision aids for psoriasis through structured searches in PubMed and grey literature sources, including institutional websites and non-indexed publications.
RESULTS: From 117 initial records, six tools met the inclusion criteria. PDAs were developed in Canada (50%), the Netherlands (33%), or the United Kingdom (17%). Half were exclusively web-based, while the others were available in both paper and digital formats. Only three tools fulfilled all formal PDA criteria: presenting evidence-based information, supporting reflection on patient values, and facilitating shared decision-making. The remaining three were classified as general decision support tools due to the absence of one or more key components. Usability testing was reported in only three tools. Target populations varied: 50% focused on moderate-to-severe psoriasis; one tool included all severities; one targeted patient with psoriasis and eczema; and another included psoriasis and atopic dermatitis. Treatment comparisons ranged from broad categories (e.g., biologics vs. conventional therapies, 33%) to specific drugs and modes of administration (66%). Visual aids were present in 33% of the tools, while 50% included a dedicated section to capture patient preferences.
CONCLUSIONS: No validated PDA currently exists for Spanish-speaking psoriasis patients. This highlights a significant unmet need for the development of a culturally adapted, accessible, and patient-centered decision aid to support informed and shared decision-making among Spanish-speaking patients.
METHODS: A defined search strategy was used to identify literature on decision aids for psoriasis through structured searches in PubMed and grey literature sources, including institutional websites and non-indexed publications.
RESULTS: From 117 initial records, six tools met the inclusion criteria. PDAs were developed in Canada (50%), the Netherlands (33%), or the United Kingdom (17%). Half were exclusively web-based, while the others were available in both paper and digital formats. Only three tools fulfilled all formal PDA criteria: presenting evidence-based information, supporting reflection on patient values, and facilitating shared decision-making. The remaining three were classified as general decision support tools due to the absence of one or more key components. Usability testing was reported in only three tools. Target populations varied: 50% focused on moderate-to-severe psoriasis; one tool included all severities; one targeted patient with psoriasis and eczema; and another included psoriasis and atopic dermatitis. Treatment comparisons ranged from broad categories (e.g., biologics vs. conventional therapies, 33%) to specific drugs and modes of administration (66%). Visual aids were present in 33% of the tools, while 50% included a dedicated section to capture patient preferences.
CONCLUSIONS: No validated PDA currently exists for Spanish-speaking psoriasis patients. This highlights a significant unmet need for the development of a culturally adapted, accessible, and patient-centered decision aid to support informed and shared decision-making among Spanish-speaking patients.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR211
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)